BioCentury on BioBusiness,
Product Discovery & Development
Table: PCSK9 data comps
Back to the parent article
Monday, November 12, 2012
Phase II proof-of-concept data presented at last week's
American Heart Association meeting in Los Angeles provide further
evidence to support the safety and efficacy of the anti-PCSK9 class of mAbs.
Cross-study comparisons are difficult but results for two of the most advanced
mAbs - REGN727 from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and
partner Sanofi (Euronext:SAN; NYSE:SNY), and AMG 145 from Amgen Inc.
(NASDAQ:AMGN) - suggest the products have comparable efficacy. Pfizer Inc.
(NYSE:PFE) also provided a first glimpse at POC data for its RN316.
AMG 145 and REGN727 were administered subcutaneously
while RN316 was delivered intravenously. (A) Maximum mean percentage changes
from baseline LDL
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]